BRENNEN

Industries / Health / Pharmaceuticals / Contract drug manufacturing

Active ingredients

Making the active pharmaceutical ingredient (API), the substance in a medicine that has the effect, by chemistry, for drug companies that do not make it themselves.

7

Milestones achieved, from 2000 to 2025.

3

To watch for: announced, not yet confirmed outside.

2

Open deliverables. Nobody has shipped them.

The road

AchievedWatch forOpen

Achieved

  1. 2000

    One rulebook for ingredients

    ICH Q7, on good manufacturing practice (GMP, the rules for making medicines consistently) for APIs, took legal effect in the EU on 1 November 2000. Its section on contract manufacturers says they must follow the same GMP, work under a written contract that sets out each side's duties, let the client audit them, and not subcontract or change the process without the client's approval.

    ema.europa.euema.europa.eu

    Credit

    ICH; EMA

  2. 2001

    Contract chemistry from China

    WuXi PharmaTech, established in Wuxi, China, in December 2000, began selling research and development services in 2001. Its 2007 filing to list in New York reported 1,972 staff, 70 customers in 2006 including nine of the ten largest drug companies, and net revenue up from USD 20.9 million in 2004 to USD 69.9 million in 2006. WuXi AppTec, which its 2026 court complaint says was established in China in 2000, describes itself as a contract research, development and manufacturing organization.

    sec.govspotlightdelaware.org

    Credit

    Ge Li and co-founders, WuXi PharmaTech

  3. 2012

    Where the rules begin

    ICH Q11, issued as FDA guidance in November 2012, sets out how a maker chooses and justifies an API's starting materials. GMP applies from the first use of a starting material, and steps that affect the API's impurities should normally sit inside the process described to regulators. That choice decides which steps a contract maker must run under GMP.

    fda.gov

    Credit

    ICH; FDA

  4. 2015

    Limits for shared plants

    From 1 June 2015 an EMA guideline asked companies that make different medicines in shared facilities to set a health-based exposure limit, such as a permitted daily exposure (PDE), for each active substance from its toxicology and clinical data. Before, certain antibiotics, hormones, cytotoxics and highly active drugs had to be made in dedicated or segregated facilities, with no official guidance on telling products within those classes apart.

    ema.europa.eu

    Credit

    EMA (adopted by its human medicines committee on 20 November 2014)

  5. 2019

    API plants counted by country

    In testimony to a US House subcommittee on 30 October 2019, Janet Woodcock, director of the FDA's drug center, said that of the plants able to make APIs for the US market in August 2019, 510 (28%) were in the United States, 230 (13%) in China and 1,048 (59%) elsewhere. She said the FDA could not tell whether or how much any plant actually produced.

    Lessona count of plants is not a measure of dependence, and the volume data needed for one were not collected.

    fda.gov

    Credit

    FDA Center for Drug Evaluation and Research

  6. 2020

    India curbs exports, then pays

    In March 2020, as the coronavirus outbreak shut factories in China, India required export licences for 26 APIs and medicines made from them, including paracetamol. A report at the time said Indian drug makers relied on China for two-thirds of the chemical components they needed. On 20 March 2020 India launched a production-linked incentive (PLI) scheme of INR 69.4 billion (6,940 crore) to make 41 bulk drugs at home; the government counted 34 projects commissioned for 25 of them by December 2024.

    Lessonan API maker is only as secure as its supplier of starting materials.

    tribuneindia.comstatic.pib.gov.in

    Credit

    India's Directorate General of Foreign Trade; Department of Pharmaceuticals

  7. 2025

    A US law on suppliers

    The BIOSECURE Act, signed on 18 December 2025 as part of the US defense authorization law, limits federal purchases and grants involving "biotechnology companies of concern". It names no companies; it uses the Pentagon's list of Chinese military companies and a process for adding others. The Pentagon put WuXi AppTec on that list on 8 June 2026, a federal court blocked the listing on 7 August, and the Pentagon removed it on 10 November 2026, "without prejudice" to relisting.

    lw.comropesgray.compublic-inspection.federalregister.gov

    Credit

    US Congress; US Department of Defense; US District Court for the District of Columbia

Watch for

  1. The first barred-supplier list

    The US Office of Management and Budget (OMB) is expected to publish its first list of biotechnology companies of concern by 18 December 2026. It could still name WuXi AppTec through a route that does not depend on the Pentagon list, and the bans would likely take effect around August 2028, with five years' grace for existing contracts.

    Achieved whenOMB publishes the list.

    ropesgray.com

    Claimed by

    Ropes & Gray, a law firm, reading the Act, November 2026

  2. A large peptide plant

    Bachem, a Swiss CDMO that makes peptides (short chains of amino acids) and oligonucleotides as APIs, says Building K at Bubendorf, opened in April 2026 and its largest plant for high-volume production, is making commercial GMP products on its first line, and that a second phase will add sales in 2027. It expects commercial production at a new site in Sisslerfeld, costing about USD 618 million, in 2030.

    Achieved whenBachem's audited annual report shows commercial sales from Building K, or a regulator's record lists the building for an approved product.

    pharmamanufacturing.com

    Claimed by

    Bachem, July 2026

  3. A second Indian scheme

    Business Standard reported on 9 November 2026 that India's Department of Pharmaceuticals is drawing up an INR 70 billion (7,000 crore) scheme covering 52 groups of related molecules and more than 300 intermediates and APIs, open to existing plants as well as new ones. By March 2026 the first scheme had paid out INR 877 million (87.70 crore) in incentives, held back by late commissioning.

    Achieved whenthe scheme is approved and notified.

    policycircle.org

    Claimed by

    the Department of Pharmaceuticals, as reported by Business Standard and Policy Circle, November 2026

Open

  1. 01

    Ingredient makers by medicine

    For each of the 370 WHO essential medicines on the US market that the FDA examined in 2019, a public list of the companies holding an active US drug master file (DMF, the file an API maker lodges with the FDA so its clients can refer to it) or a European certificate of suitability (CEP) for its API, with each holder's country, refreshed every quarter. It shows who can supply, not who does.

    The brief
    Credit · unclaimed
  2. 02

    Exposure limits in one table

    A public table of published permitted daily exposure values for APIs, with each value's source, its starting point (the dose used as the point of departure) and the adjustment factors applied, so that a shared plant can see where companies disagree.

    The brief
    Credit · unclaimed

Open 01 · the brief

Ingredient makers by medicine

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

For each of the 370 WHO essential medicines on the US market that the FDA examined in 2019, a public list of the companies holding an active US drug master file (DMF, the file an API maker lodges with the FDA so its clients can refer to it) or a European certificate of suitability (CEP) for its API, with each holder's country, refreshed every quarter. It shows who can supply, not who does.

Why it is still open

Finished-medicine makers do not disclose who makes their API. The one product-level mapping, the US Pharmacopeia's Medicine Supply Map, uses public and proprietary sources (Brookings, July 2025). Buyer marketplaces such as Pharmaoffer list the European certificate holders for one ingredient at a time, with their countries, so that buyers can ask for quotes. The FDA said in 2019 that it lacked production data. I found no free table, one row per medicine, that joins the US and European filings.

brookings.edufda.govpharmaoffer.com

Built with what exists

the FDA's quarterly DMF list (third quarter 2026, a 51.5 MB spreadsheet); the European Directorate for the Quality of Medicines' certificates catalogue (holder name, CEP type and number); a language model to match holder names to countries, with a person checking each match.

fda.govextranet.edqm.eu

  1. First step

    Download the third-quarter 2026 DMF list and map the active API holders for 20 essential medicines.

  2. Done looks like

    370 medicines, each with holder counts by country and a link per holder; country shares compared with the FDA's 2019 figures; fewer than 2% errors in a hand check of 200 rows.

Open 02 · the brief

Exposure limits in one table

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A public table of published permitted daily exposure values for APIs, with each value's source, its starting point (the dose used as the point of departure) and the adjustment factors applied, so that a shared plant can see where companies disagree.

Why it is still open

There are no official PDE lists for medicines, so each company sets its own. A 2024 comparison by authors from ten drug makers and a consultancy, led by Claudia Sehner of Boehringer Ingelheim, covered five APIs and found spreads below ten-fold, largest for morphine. Shared tables exist only behind a fee or a membership: Lhasa Limited has run a database since 2017 in which member drug companies share such limits, and GMP-Verlag sells PDE reports for more than 2,500 APIs. Open calculators such as pde-calculator on GitHub (2026) compute new values but do not collect published ones.

eutils.ncbi.nlm.nih.govlhasalimited.orggmp-publishing.com

Built with what exists

the Europe PMC and PubMed search interfaces to find published PDE monographs; the fields of the EMA 2014 guideline as the table's columns; a language model to extract values, with a person checking each one; pde-calculator as a cross-check.

  1. First step

    Collect the published values for the five APIs in the 2024 comparison and 20 more, and check each against its paper.

  2. Done looks like

    100 APIs, each with every published value, its inputs and the ratio of highest to lowest value, and the five APIs of the 2024 comparison reproduced.